Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Evidence of the Month PowerPoint Presentation
Download Presentation
Evidence of the Month

Evidence of the Month

223 Views Download Presentation
Download Presentation

Evidence of the Month

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

    1. Evidence of the Month Comment on: A randomized trial of therapies for type 2 diabetes and coronary artery disease

    2. BARI 2D methods/primary end points Participants 2368 with Type 2 diabetes and angiographically documented stable ischaemic heart disease Mean age 62.4 years, 10.4 years average duration of diabetes, 32% with MI history, 30.7% with triple-vessel disease Randomization Either prompt revascularization or intensive medical therapy alone (delayed revascularization could take place if needed during the trial) and Either insulin-sensitizing therapy (mainly metformin and rosiglitazone) or insulin-providing therapy (sulfonylurea and insulin) End points Rate of death and major cardiovascular events (death, MI, or stroke) over 5 years

    3. Enrollment and randomization

    4. Survival outcomes: revascularization (CABG or PCI) vs medical therapy

    5. Survival outcomes: insulin sensitization vs insulin provision

    6. Freedom from major cardiovascular events: insulin sensitization vs insulin provision

    7. Freedom from major cardiovascular events: CABG vs medical therapy

    8. Clinical implications Prompt revascularization and intensive medical therapy alone offer comparable cardioprotection for individuals with Type 2 diabetes and stable ischaemic heart disease Insulin-providing and insulin-sensitizing glucose control strategies offer comparable cardioprotection; however, insulin sensitization is associated with lower HbA1c, less hypoglycaemia, lower plasma insulin, less weight gain, and higher high-density lipoprotein cholesterol Prompt CABG is associated with significantly greater cardioprotection than medical therapy alone, when CABG is needed; CABG/insulin-sensitizing therapy offers greatest protection Initial treatment with medication alone is a safe and effective option for most Type 2 diabetes patients with stable ischaemic heart disease BARI 2D reduces concerns about the cardiovascular safety of glucose control strategies and supports insulin sensitization and provision as reasonable treatment options